Dual-Chamber Drug Delivery Patent, Semaglutide and Cagrilintide
Summary
USPTO Application US20260108587A1, published April 23, 2026, covers aqueous pharmaceutical formulations of semaglutide and cagrilintide designed for co-administration via a dual-chamber medical device. The inventors are Tommy Sander, Christian Poulsen, and Rosa Rebecca Erritzoee Hansen. Filing date was December 17, 2025, under Application No. 19423120. CPC classifications include A61K 38/26 (GLP-1 peptides), A61M 5/19 (infusion devices), and various formulation excipients.
“Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide.”
About this source
USPTO classification A61M covers devices that introduce or withdraw fluids from the body: infusion pumps, catheters, syringes, inhalers, wound drainage, dialysis equipment, and fluid-handling microfluidics. Every newly published application in A61M lands in this feed, around 205 a month. Applications publish 18 months after filing. Watch this if you compete in infusion therapy or drug delivery, file freedom-to-operate analyses for medical device startups, scout acquisition targets in cardiovascular or respiratory devices, or track hospital R&D arms that are quietly patenting clinical innovations.
What changed
USPTO published patent application US20260108587A1 for an aqueous pharmaceutical formulation comprising cagrilintide and a separate aqueous formulation comprising semaglutide, both designed for presentation and administration using a dual-chamber medical device.
Pharmaceutical companies developing GLP-1 combination therapies should review this filing for potential freedom-to-operate implications, as the dual-chamber device design and specific formulation combinations may represent competitive IP landscape considerations.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL FORMULATIONS
Application US20260108587A1 Kind: A1 Apr 23, 2026
Inventors
Tommy Sander, Christian Poulsen, Rosa Rebecca Erritzoee Hansen
Abstract
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.
CPC Classifications
A61K 38/26 A61K 9/0019 A61K 9/08 A61K 31/4172 A61K 38/1703 A61K 47/02 A61K 47/10 A61K 47/12 A61K 47/183 A61K 47/22 A61K 47/24 A61K 47/26 A61M 5/19
Filing Date
2025-12-17
Application No.
19423120
Related changes
Get daily alerts for USPTO Patent Applications - Medical Devices (A61M)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Medical Devices (A61M) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.